Company profile
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology: Pharmaceutical Preparations
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06488313 | phase2 | recruiting | 2024-11-04 | 2026-06-01 | Arcturus Therapeutics, Inc. | A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD |
| NCT04668339 | phase2 | terminated | 2021-01-07 | 2022-03-01 | Arcturus Therapeutics, Inc. | A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults |
| NCT05037097 | phase1_2 | completed | 2021-08-30 | 2023-12-19 | Arcturus Therapeutics, Inc. | A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults |
| NCT04480957 | phase1_2 | completed | 2020-08-04 | 2021-01-29 | Arcturus Therapeutics, Inc. | Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects |
| NCT06279871 | phase3 | completed | 2024-03-27 | 2024-10-09 | Arcturus Therapeutics, Inc. | Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults |
FDA applications (0)
No records yet.